drugset
Drugs / Mifomelatide
last change Apr 2025 re-read 3 minutes ago

Mifomelatide

also known as Mifomelatida · TCMCB07

Protein / enzyme biologic

Developed for
pancreatic ductal adenocarcinoma
Investigated by
Endevica Bio

Trials 2

today NCT06937177 · Ph 2
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT06937177 Apr 2025 → Oct 2027 expected — Endevica Bio Recruiting No outcome recorded
Phase not stated1 trial
— NCT07399015 — pancreatic ductal adenocarcinoma Endevica Bio No longer available No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2024-11-07 Endevica Bio Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats endevicabio.com ↗
2023-10-28 Endevica Bio Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia endevicabio.com ↗
2023-05-20 Endevica Bio Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects. endevicabio.com ↗
2023-05-20 Endevica Bio Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in rats. endevicabio.com ↗
2021-05-20 Endevica Bio Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs endevicabio.com ↗
2020-07-29 Endevica Bio Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07 endevicabio.com ↗
2020-06-16 Endevica Bio Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexia endevicabio.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Mifomelatide “Mifomelatide (TCMCB07) 12.5 mg administered subcutaneously daily for 12 weeks” NCT06937177 ↗
1

NCT07399015 ↗
Known as Mifomelatida ChEMBL registry synonym — accepted as the source's own label CHEMBL6068142 ↗
Known as TCMCB07 “Mifomelatide (TCMCB07) 12.5 mg administered subcutaneously daily for 12 weeks” NCT06937177 ↗
Modality Protein / enzyme biologic — CHEMBL6068142 ↗
Route Subcutaneous “administered daily by subcutaneous (SC) injection” NCT06937177 ↗